COVID-19 and Acute Renal Failure

Overview

About this study

The primary purpose of this study is to examine 1-year survival and rate of secondary infections in COVID-19 patients with and without acute kidney injury (AKI).

 

 

 

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria: 

  • Adult patients, ≥ 18 years of age.
  • Patients testing positive for SARS-CoV-2 and requiring hospitalization at the Mayo Clinic Arizona, Rochester, or Florida campuses.

Exclusion Criteria:

  • Patients < 18 years of age.
  • Patients with pre-existing end-stage renal disease; i.e., need for renal replacement therapy (RRT) prior to index hospitalization.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Jacksonville, Fla.

Mayo Clinic principal investigator

Kai Singbartl, M.D.

Open for enrollment

Contact information:

Kai Singbartl M.D.

(480) 342-1376

Singbartl.Kai@mayo.edu

Scottsdale/Phoenix, Ariz.

Mayo Clinic principal investigator

Kai Singbartl, M.D.

Open for enrollment

Contact information:

Kai Singbartl M.D.

(480) 342-1376

Singbartl.Kai@mayo.edu

Rochester, Minn.

Mayo Clinic principal investigator

Kai Singbartl, M.D.

Open for enrollment

Contact information:

Kai Singbartl M.D.

(480) 342-1376

Singbartl.Kai@mayo.edu

More information

Publications

Publications are currently not available

Study Results Summary

Not yet available

Supplemental Study Information

Not yet available

.
CLS-20503086

Mayo Clinic Footer